CorrespondenceHypertension and ascorbic acid
References (5)
- et al.
Treatment of hypertension with ascorbic acid
Lancet
(1999) Haemostatic vitamins and prostaglandins
Med J Australia
(1982)
Cited by (13)
Vitamin C for Type 2 Diabetes Mellitus and Hypertension
2019, Archives of Medical ResearchNutritional factors in the prevention and management of coronary artery disease and heart failure
2015, NutritionCitation Excerpt :This implies that PUFAs themselves may not be able to bring about all their benefits and possibly, they need to be metabolized to their beneficial products such as PGE1, PGI2, PGI3, lipoxins, resolvins, and protectins and enhance the formation of endothelial nitric oxide, which have antiatheroslcerotic, antiplatelet, and vasodilator actions that account for their protective action against CAD and HF. It is known that many cofactors are needed for the conversion of the administered/endogenous PUFAs to their beneficial metabolites, some of which include minerals, vitamins, and trace elements [9,10,13] and hence, their availability in adequate amounts is equally essential to derive their benefits. Additionally, conversion of dietary EFAs (linoleic acid [LA] and α-linolenic acid [ALA]) to their respective long-chain metabolites AA and EPA, and DHA, respectively, need adequate activities of enzymes Δ6 and Δ5 desaturases and elongases, and for the formation of their respective PGs, leukotrienes, thromboxanes, lipoxins, resolvins, and protectins physiologically active COXs and 5-, 12-, and 15-lipoxygenases are essential (Fig. 1).
Nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension
2005, Progress in Cardiovascular DiseasesIs insulin an antiinflammatory molecule?
2001, NutritionBeneficial effect(s) of n-3 fatty acids in cardiovascular diseases: But, why and how?
2000, Prostaglandins Leukotrienes and Essential Fatty Acids